GOSS
Gossamer Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.73
−10.13%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$12.00
From 52W high−96.46%
Volume526385.00
Market cap$65.63M
P/E (TTM)—
P/S (TTM)1.2x
Div yield—
Key dataSep 18, 2026
Open
$12.00
From 52W high
−96.46%
Volume
526385.00
Market cap
$65.63M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
47.4
MomentumView details →
1D Return
−10.13%
YTD Return
−95.06%
SummaryUpdated Jun 1, 2026
Gossamer Bio, Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in San Diego, California. The company went public in February 2019 and focuses on discovering, acquiring, developing, and commercializing innovative therapeutics targeting immunology, inflammation, and oncology. Originally incorporated as FSG Bio, Inc., the company changed its name to Gossamer Bio in 2017. Gossamer Bio operates as a development-stage biotechnology company with multiple drug candidates in various phases of clinical trials, positioning itself to address significant unmet medical needs in rare and serious diseases.
Similar companies
Latest newsMore news →
Gossamer Bio, Inc. appointed Gregory A. Ciongoli as a Class III director effective September 16, 2026, with an annual base salary of $40,000 and an initial equity award to be determined later.4d agoGossamer Bio, Inc. filed a Certificate of Amendment with the Delaware Secretary of State to effect a 1-for-80 reverse stock split.9d agoGossamer Bio announced at the Cantor Fitzgerald healthcare conference that the FDA has given a constructive signal on seralutinib, with an acting director stating 'We have no issue with filing,' and the company plans to submit its new drug application in late September 2024.11d ago